Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 studyYuankai Shi, Jifeng Feng, Xiuhua Sun et al.|BMC Cancer|2024Cited by 4
Decreased placental TLR3 is associated with hepatitis B virus vaccine responsiveness in infants born to HBsAg-positive mothersLina Wu, Suping Wang, Gan Fu et al.|Translational Pediatrics|2023Cited by 3